NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary , Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network
NRx Pharmaceuticals Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application
NRx Pharmaceuticals Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
HOPE Therapeutics, an NRx Subsidiary Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
NRx Pharmaceuticals Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
Quebec Innovative Materials Corp. Announces U.S. Affiliate Orvian Receives Minnesota DNR Registration for Exploratory Boring
